New hope for kids with Hard-to-Treat cancers: entrectinib trial opens
NCT ID NCT02650401
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 33 times
Summary
This study tests an experimental drug called entrectinib in children and teens with advanced solid tumors or brain cancers that have come back or not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors, especially in those with specific gene changes (NTRK or ROS1 fusions). About 69 participants will receive the drug by mouth or feeding tube, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, China
-
Centre Leon Berard
Lyon, 69373, France
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Egleston Children's Hospital at Emory University Atlanta
Atlanta, Georgia, 30322, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
Hong Kong Children's Hospital
Hong Kong, 00000, Hong Kong
-
Hospital Infantil Universitario Nino Jesus
Madrid, 28009, Spain
-
Hôpital de la Timone, Oncologie Pédiatrique
Marseille, 13385, France
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Oregon Health & Science Uni
Portland, Oregon, 97239, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Royal Marsden Hospital (Sutton)
London, SW3 6JJ, United Kingdom
-
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
St. Jude Children'S Research Hospital
Memphis, Tennessee, 38105, United States
-
Texas Children's Cancer and Hematology Center
Houston, Texas, 77030, United States
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
UCSF Benioff Children's Hospital
San Francisco, California, 94158, United States
-
Universitaetsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, 69120, Germany
-
University of California San Diego
La Jolla, California, 92093-0706, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Washington University,St. Louis Children's Hospital
St Louis, Missouri, 63110, United States
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200082, China
Conditions
Explore the condition pages connected to this study.